Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) have earned a consensus rating of “Buy” from the ten brokerages that are currently covering the firm. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $6.71.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Wednesday, November 9th. FBR & Co reissued a “buy” rating and issued a $6.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 8th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 8th. JPMorgan Chase & Co. reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, August 5th. Finally, JMP Securities lowered BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th.

In other news, VP Alane P. Barnes sold 8,357 shares of the company’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $4.27, for a total transaction of $35,684.39. Following the sale, the vice president now owns 79,377 shares of the company’s stock, valued at $338,939.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.80% of the company’s stock.

Several institutional investors have recently modified their holdings of BCRX. Janney Montgomery Scott LLC increased its position in shares of BioCryst Pharmaceuticals by 1.0% in the second quarter. Janney Montgomery Scott LLC now owns 25,935 shares of the biotechnology company’s stock worth $268,000 after buying an additional 250 shares during the last quarter. California State Teachers Retirement System increased its position in shares of BioCryst Pharmaceuticals by 0.3% in the second quarter. California State Teachers Retirement System now owns 154,083 shares of the biotechnology company’s stock worth $438,000 after buying an additional 500 shares during the last quarter. ProShare Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 1.4% in the second quarter. ProShare Advisors LLC now owns 63,843 shares of the biotechnology company’s stock worth $181,000 after buying an additional 876 shares during the last quarter. BlackRock Group LTD increased its position in shares of BioCryst Pharmaceuticals by 4.4% in the third quarter. BlackRock Group LTD now owns 23,530 shares of the biotechnology company’s stock worth $104,000 after buying an additional 984 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 245,729 shares of the biotechnology company’s stock worth $698,000 after buying an additional 3,528 shares during the last quarter. Hedge funds and other institutional investors own 76.72% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was published by Daily Political and is the propert of of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of United States and international copyright law. The correct version of this article can be viewed at http://www.dailypolitical.com/2016/11/30/brokerages-set-biocryst-pharmaceuticals-inc-bcrx-target-price-at-6-71.html.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.59 on Monday. The stock’s market cap is $412.31 million. The stock’s 50 day moving average price is $4.78 and its 200 day moving average price is $4.01. BioCryst Pharmaceuticals has a one year low of $1.63 and a one year high of $10.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.08. The firm had revenue of $7.80 million for the quarter, compared to analyst estimates of $5.94 million. BioCryst Pharmaceuticals had a negative net margin of 313.02% and a negative return on equity of 296.19%. The business’s revenue for the quarter was down 29.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.20) EPS. Analysts forecast that BioCryst Pharmaceuticals will post ($0.92) earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

5 Day Chart for NASDAQ:BCRX

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.